Biotech collaboration established to commercialize research reagents

October 18th, 2010
The Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, has entered a collaboration with New Jersey-based medical technology company BD to evaluate and potentially develop for research and diagnostic use some of the institute's reagents.

The institute has a portfolio of more than 100 monoclonal antibodies produced through its in-house antibody facility for research into cancer, chronic inflammatory diseases and infectious diseases.

The collaboration, with BD's Biosciences segment, will build on programs at the institute that are focused on identifying novel targets for therapeutic monoclonal antibody and drug development.

Under the terms of the agreement, BD will make upfront and annual payments to the institute as well as royalty payments on sales of any licensed antibodies in return for a first option to evaluate and commercialise antibodies from the institute. The financial terms of the collaboration are confidential.

The institute's business development manager Dr James Dromey said antibodies were an important tool in the lab as well as the clinic, where they are used as diagnostic tools and biomarkers.

"This is a wonderful opportunity for the institute to share its internal resources and scientific expertise with the wider scientific community and to improve the possibility of the institute's technology being commercialised and having a positive impact on research and diagnostic markets," Dr Dromey said.

"The institute's strategic research interests align well with those of BD, particularly in key areas such as cancer, programmed cell death (apoptosis), stem cells and immunology. This is the first commercial contract that we have established for wider utilisation of institute reagents, and we hope it will be the first step in a broader collaboration with BD."

The institute has a track record for producing commercially available and successful products, including the LIF protein, which is essential for the maintenance of embryonic stem cells, and the pGex fusion protein vector.

Antibody production and related services form one of the most important technology platforms that underpin the institute's successful science and commercialisation activities. The institute's 'discovery pipeline' is fed by more than 250 research projects, many involving development of new antibodies through its in-house antibody facility.

Provided by Walter and Eliza Hall Institute

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Team infuses science into 'Minecraft' modification

The 3-D world of the popular "Minecraft" video game just became more entertaining, perilous and educational, thanks to a comprehensive code modification kit, "Polycraft World," created by University of Texas at Dallas professors, ...

States ascend into the cloud

Seven years ago, the state of Delaware started moving computer servers out of closets and from under workers' desks to create a consolidated data center and a virtual computing climate.

Volunteer guidelines for clinicians in the Ebola epidemic

Disaster Medicine and Public Health Preparedness Journal has released a novel, informative article that speaks to volunteers within the Ebola epidemic. The article, contributed by a consortium of Boston-based hospitals, is ent ...